Salsabila Putri Khairani

Salsabila Putri Khairani

Auto-generated profile, based on publicly available information

Salsabila Putri Khairani

Biomedical Science Padang West Sumatra Universitas Andalas Faculty of Medicine

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Journal of Herbmed Pharmacology
Verified
Journal Article
Open access
PDF file
SKSalsabila Putri Khairani
Salsabila Putri Khairani
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
ZRZerlina Dwi Ramadhannisa
Zerlina Dwi Ramadhannisa
ARAldi Tamara Rahman
Aldi Tamara Rahman
DADessy Arisanty
Dessy Arisanty
NHNoza Hilbertina
Noza Hilbertina
Introduction: Breast cancer remains a prevalent global malignancy and necessitates a treatment regimen, which is often accompanied by substantial side effects. To address this challenge, alternative therapies with fewer adverse effects are urgently needed. Amomum cardamomum has displayed promising anticancer potential. This study aimed to investigate the impact of A. cardamomum seed on T47D breast cancer cell viability and the ability to induce apoptosis, utilizing in silico and in vitro approaches. Methods: The samples were extracted utilizing the maceration method using ethanol 96% solvent. In addition, the bioactive constituents were identified through phytochemicals and GC/MS analysis. Cell viability was assessed through MTT assay at various concentrations with 24 and 48-hour incubation periods and compared with the control cells. Apoptosis patterns were visualized by Immunofluorescence assay and analyzed utilizing ImageJ software. In silico analyses included three distinct tests, namely pharmacokinetics analysis (ADMET), bioactivity prediction (PASS), and molecular docking. Results: The A. cardamomum seed extract inhibited the growth of the cells with an IC50 value of 97.28 μg/mL in 48 hours of the incubation period. Immunofluorescence assay exhibited that the extract induced apoptosis in over 50% of T47D cells. In silico approaches identified bicyclogermacrene, Germacrene-D, and δ-cadinene as potential JAK3, BRAF v600e, and MMP9 protein inhibitors. These compounds exhibited stronger binding affinities to critical amino acids than control ligands. Conclusion: This research presents compelling evidence that the A. cardamomum extract has anticancer activity against breast cancer by preventing growth and inducing apoptosis.

1 January 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
RRRauza Sukma Rita
Rauza Sukma Rita
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
SKSalsabila P. Khairani
Salsabila P. Khairani
RPRizky E. Putera
Rizky E. Putera
VAVella Amalia
Vella Amalia
AKAndi A. D. Kahar
Andi A. D. Kahar
Context: Colorectal cancer (CRC) remains a significant global health challenge despite advances in treatment modalities. The coelomic fluid of Lytechinus variegatus emerges as a rich source of bioactive peptides with the potential as a new therapeutic anticancer agent. Aims: To analyze the toxicity, allergenicity, and potential of L. variegatus coelomic fluid peptides as multitarget inhibitor agents of CRC cancer cells through an in silico study. Methods: Ten peptides from L. variegatus coelomic fluid were processed using UCSF Chimera software to model the three-dimensional structure. ToxinPred and AllerTop web servers were used to analyze the toxicity and allergenicity of peptides, respectively. The 3D structures of EGFR, AKT1, GSK3B, VEGFR2, and JAK3 were retrieved from the PDBJ database. MOE Software was used to perform molecular docking. Results: Peptide 4 binds to the ATP binding pocket of GSK3B protein with the strongest binding affinity value (-8,68 kcal/mol). The docking results between EGFR and peptides showed that peptide 10 binds to the ATP binding pocket with the lowest binding affinity (-9.52 kcal/mol). Peptide 2 binds to the ATP binding pocket of AKT1 with the lowest binding affinity value (-9.16 kcal/mol). Peptide 3 has the lowest binding affinity value of the JAK3 ATP binding pocket (-8,67 kcal/mol). Peptide 7 binds to the ATP binding pocket of VEGFR2 with the strongest binding affinity (-9,67 kcal/mol). Conclusions: The L. variegatus peptides have the potential as multitarget anti-CRC agents by inhibiting the activity of GSK3B, EGFR, AKT1, JAK3, and VEGFR2 proteins through the ATP competitive inhibitor action based on in silico study.

21 April 2025 in Narra J
Verified
Journal Article
Open access
PDF file
DADessy Arisanty
Dessy Arisanty
SKSalsabila P. Khairani
Salsabila P. Khairani
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
DWDhyani P. Wahyudi
Dhyani P. Wahyudi
IKIsna C. Kamila
Isna C. Kamila
AAAl H. Ariouso
Al H. Ariouso
Atherosclerosis is a leading cardiovascular disease characterized by the buildup of plaques within arterial walls. The aim of this study was to investigate the potential of peptides derived from Lytechinus variegatus spines as novel therapeutic agents for atherosclerosis using an in silico approach. Key proteins involved in atherosclerosis were selected as target proteins: vascular endothelial growth factor receptor (VEGFR), protein kinase B (AKT1), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 8 (MAPK8), and endothelin-1 (ET-1). Comprehensive analysis involving ligand and protein preparation, toxicity, and allergenicity assessments, absorption, distribution, metabolism and excretion (ADME) predictions, and molecular docking were conducted to evaluate the safety, pharmacokinetic properties, binding affinity (kcal/mol), root mean square deviation (RMSD) (Å), as well as a 2D and 3D visualization. Toxicity predictions revealed that peptide 9 was non-toxic and non-allergenic, with a lethal dose 50 (LD50) of 3,000 mg/kg, indicating its safety. Peptide 9 demonstrated the most promising results, effectively inhibiting VEGFR2 (-10,90 kcal/mol), AKT1 (-10,56 kcal/mol), EGFR (-9,82 kcal/mol), MAPK8 (-9,64 kcal/mol), and ET-1 (-11,41 kcal/mol) with strong binding affinities and specificity. These interactions suggested that peptide 9 from Lytechinus variegatus spines may serve as a competitive multitarget inhibitor, offering potential multitarget therapeutic activity against atherosclerosis. Peptide 9 also had high water solubility and did not affect the concentration or excretion of other drugs or compounds, minimizing the risk of drug-drug interactions.

6 August 2026 in F1000Research
Verified
Journal Article
Open access
PDF file
DADessy Arisanty
Dessy Arisanty
SKSalsabila Putri Khairani
Salsabila Putri Khairani
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
ARAldi Tamara Rahman
Aldi Tamara Rahman
CTChristopher Daniel Tristan
Christopher Daniel Tristan
KSKuni Zakiyyah Sumargo
Kuni Zakiyyah Sumargo
Background Breast cancer remains one of the leading causes of cancer-related mortality worldwide, and the emergence of drug resistance, systemic toxicity, and limited efficacy of current therapies highlight the need for safer and more effective treatment. Natural products have emerged as promising sources of multi-target anticancer agents. A. cardamomum has demonstrated preliminary anticancer potential, yet the bioactive constituents and their molecular mechanisms in breast cancer remain poorly elucidated. Methods This study integrated in silico approaches to investigate the therapeutic potential of A. cardamomum seed extract against breast cancer. LC–MS analysis identified phytochemical compounds, followed by network pharmacology to determine their potential targets and molecular pathways. Pharmacokinetic and toxicity predictions were assessed through ADMET and Lipinski’s rule of five analyses to evaluate drug-likeness and safety. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate binding affinity and structural stability of compounds with key oncogenic proteins. Results LC-MS profiling identified 22 distinct compounds in A. cardamomum seeds. ADMET and Lipinski analyses demonstrated that most compounds possessed high gastrointestinal absorption, favorable oral bioavailability, and low toxicity risk. Network pharmacology highlighting SRC, TNF-α, Caspase-3, and EGFR as central nodes in the protein-protein interaction network. Molecular docking identified compounds C17 and C20 as the most promising bioactives, showing strong binding affinities and interactions similar to control ligands. MD simulations confirmed their stable complexes, indicating conformational stability and robust ligand–protein interactions. Conclusion This study highlights the promising multi-target anticancer potential of A. cardamomum seeds. Compounds C17 and C20 were identified as lead candidates with strong and stable interactions with key breast cancer-related proteins and favorable pharmacokinetic properties. These results suggest that A. cardamomum could serve as a potential source for developing new plant-based therapies against breast cancer. Further in vitro and in vivo investigations are warranted to validate their efficacy and safety.

8 December 2025 in F1000Research
Verified
Journal Article
Open access
PDF file
DADessy Arisanty
Dessy Arisanty
SKSalsabila Putri Khairani
Salsabila Putri Khairani
KCKevin Nathaniel Cuandra
Kevin Nathaniel Cuandra
ARAldi Tamara Rahman
Aldi Tamara Rahman
CTChristopher Daniel Tristan
Christopher Daniel Tristan
KSKuni Zakiyyah Sumargo
Kuni Zakiyyah Sumargo
Background Breast cancer remains one of the leading causes of cancer-related mortality worldwide, and the emergence of drug resistance, systemic toxicity, and limited efficacy of current therapies highlight the need for safer and more effective treatment. Natural products have emerged as promising sources of multi-target anticancer agents. A. cardamomum has demonstrated preliminary anticancer potential, yet the bioactive constituents and their molecular mechanisms in breast cancer remain poorly elucidated. Methods This study integrated in silico approaches to investigate the therapeutic potential of A. cardamomum seed extract against breast cancer. LC–MS analysis identified phytochemical compounds, followed by network pharmacology to determine their potential targets and molecular pathways. Pharmacokinetic and toxicity predictions were assessed through ADMET and Lipinski’s rule of five analyses to evaluate drug-likeness and safety. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate binding affinity and structural stability of compounds with key oncogenic proteins. Results LC-MS profiling identified 22 distinct compounds in A. cardamomum seeds. ADMET and Lipinski analyses demonstrated that most compounds possessed high gastrointestinal absorption, favorable oral bioavailability, and low toxicity risk. Network pharmacology highlighting SRC, TNF-α, Caspase-3, and EGFR as central nodes in the protein-protein interaction network. Molecular docking identified compounds C17 and C20 as the most promising bioactives, showing strong binding affinities and interactions similar to control ligands. MD simulations confirmed their stable complexes, indicating conformational stability and robust ligand–protein interactions. Conclusion This study highlights the promising multi-target anticancer potential of A. cardamomum seeds. Compounds C17 and C20 were identified as lead candidates with strong and stable interactions with key breast cancer-related proteins and favorable pharmacokinetic properties. These results suggest that A. cardamomum could serve as a potential source for developing new plant-based therapies against breast cancer. Further in vitro and in vivo investigations are warranted to validate their efficacy and safety.

6 December 2025 in Jurnal Kimia Sains dan Aplikasi
Verified
Journal Article
Open access
DADessy Arisanty
Dessy Arisanty
ZEzolkapli bin eshak
zolkapli bin eshak
FWFatma Sri Wahyuni
Fatma Sri Wahyuni
AAAfifatul Achyar
Afifatul Achyar
SKSalsabila Putri Khairani
Salsabila Putri Khairani
Breast cancer remains one of the leading causes of death in women worldwide, with high incidence and mortality rates. The abnormal expression of the small non-coding RNA, microRNA-10b (miR-10b), has been associated with breast cancer progression. miR-10b is involved in various biological processes, including proliferation, metastasis, and drug resistance. However, the underlying mechanism by which miR-10b contributes to breast cancer progression remains unclear. This study aimed to investigate the effect of miR-10b on the expression of HOXD10 and PI3K genes, as well as its impact on cell viability and proliferation in breast cancer cells. In this study, T47D breast cancer cells were transfected with mimic miR-10b using the FANA-oligo transfection method at concentrations of 1, 2.5, and 5 µM. Cell viability was assessed using the MTT assay, while HOXD10 and PI3K gene expression levels were measured using RT-qPCR and ELISA. Data were analysed using paired t-tests with SPSS, and results were considered statistically significant at p < 0.05. The results showed that mimic miR-10b induced a dose-dependent increase in cell proliferation. Notably, only HOXD10 gene expression was significantly affected by the transfection, while PI3K gene expression remained unchanged. Cells transfected with 5 µM miR-10b mimic exhibited the highest proliferation rate compared to non-transfected controls (p < 0.05). In conclusion, miR-10b promotes breast cancer cell proliferation by downregulating HOXD10 expression, independent of PI3K, suggesting it is a potential target for further investigation.